Yüklüyor......

Bayesian designs to account for patient heterogeneity in phase II clinical trials

PURPOSE OF REVIEW: Between-patient heterogeneity is very common in clinical trials. This complicates treatment evaluation, due to known prognostic subgroup effects or potential treatment-subgroup interactions. We review two Bayesian phase II clinical trial designs that account explicitly for patient...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Curr Opin Oncol
Asıl Yazarlar: Thall, Peter F., Wathen, J. Kyle
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: 2008
Konular:
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC5555403/
https://ncbi.nlm.nih.gov/pubmed/18525336
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CCO.0b013e328302163c
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!